RESUMO
Objectives: Home- and community-based services (HCBS) help older adults to remain active in community settings. However, it is not known if there is a causal relationship between HCBS and social engagement. Methods: We used data from the 2010 and 2012 Health and Retirement Study and measured the effect of HCBS on social engagement via nearest-neighbor Mahalanobis matching, optimal pair matching, genetic matching, and optimal full matching. Results: Genetic matching showed that the odds of social engagement for participants who received at least one HCBS (congregate meal, home-delivered meal, transportation service, case management, homemaker or housekeeping services, or caregiver services) in the prior two years was 1.07 times more likely than participants who have not received any HCBS (robust SE = .030, p = .040). Discussion: HCBS may remove barriers to social engagement through increasing older adults' personal resources and personal networks.
Assuntos
Serviços de Saúde Comunitária , Serviços de Assistência Domiciliar , Humanos , Estados Unidos , Idoso , Participação Social , Cuidadores , MedicaidRESUMO
BACKGROUND: Mild traumatic brain injury (MTBI) causes morbidity and disability worldwide. Pediatric patients are uniquely vulnerable due to developmental and psychosocial factors. Reduced healthcare access in rural/underserved communities impair management and outcome. A knowledge update relevant to current gaps in care is critically needed to develop targeted solutions. METHODS: The National Library of Medicine PubMed database was queried using comprehensive search terms (("mild traumatic brain injury" or "concussion") and ("rural" or "low-income" or "underserved") and ("pediatric" or "child/children")) in the title, abstract, and Medical Subject Headings through December 2022. Fifteen articles on rural/underserved pediatric MTBI/concussion not covered in prior reviews were examined and organized into four topical categories: epidemiology, care practices, socioeconomic factors, and telehealth. RESULTS: Incidences are higher for Individuals in rural regions, minorities, and those aged 0-4 years compared to their counterparts, and are increasing over time. Rural healthcare utilization rates generally exceed urban rates, and favor emergency departments (vs. primary care) for initial injury assessment. Management guidelines require customization to resource-constrained settings for implementation and adoption. Decreased community recognition of the seriousness of injury is a consensus challenge to care provision by clinicians. Low parental education and income were correlated with decreased MTBI knowledge and worse outcome. Telehealth protocols for triage/consultation and rehabilitation were feasible in improving care delivery to rural and remote settings. CONCLUSIONS: Pediatric MTBI/concussion patients in rural/underserved regions experience increased risks of injury, geographic and financial healthcare barriers, and poorer outcomes. Globally, under-reporting of injury has hindered epidemiological understanding. Ongoing MTBI education should be implemented for rural caregivers, schools, and low-income populations to improve community awareness. Telehealth can improve care delivery across acuity settings, and warrants judicious inclusion in triage and treatment protocols.
RESUMO
OBJECTIVES: The purpose of this study was to evaluate the impact of antidiabetic medication adherence on hospital utilization in patients with newly diagnosed type 2 diabetes mellitus (T2D). This study specifically analyzed patients with newly diagnosed T2D with the intent of lessening intragroup disease severity differences, and adjusting for a range of other clinical and demographic characteristics. METHODS: This retrospective US claims database study evaluated adults with newly diagnosed T2D who started antidiabetic medications in 2005-2009, had ≥ 2 antidiabetic medication claims after their first (baseline). Medication adherence was evaluated using the medication possession ratio (MPR) of any or all antidiabetic medication(s) during the 3-year post-baseline period. Repeated-measures analyses examined changes in inpatient utilization from the pre- to post-baseline period. The impact of adherence on hospital utilization during the post-baseline period was evaluated with a logistic regression model to adjust for confounding factors. RESULTS: The study included 192,717 patients (mean age, 55.0 years). Mean MPR for antidiabetic therapy was 0.74. MPR was highest in elderly patients and Medicare beneficiaries. Mean annualized inpatient admissions during the 3-year post-baseline period were significantly lower in patients with MPR ≥ 0.80 (1.4) than in those with MPR < 0.80 (2.2; P < 0.05). Logistic regression analysis, adjusting for patient characteristics and prior inpatient utilization, showed 39% lower odds of hospitalization (OR = 0.61; 95% CI = 0.534-0.693) for patients with MPR ≥ 0.80. People with T2D-related complications or hospitalization had approximately 2- to 3-fold higher risk of subsequent hospitalization. CONCLUSIONS: In newly diagnosed T2D patients with antidiabetic therapy in the first three ensuing years, higher antidiabetic medication adherence was significantly associated with lower hospital inpatient utilization before and after adjusting for patient characteristics.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hospitalização/estatística & dados numéricos , Adesão à Medicação/estatística & dados numéricos , Demandas Administrativas em Assistência à Saúde , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Bases de Dados Factuais , Diabetes Mellitus Tipo 2/diagnóstico , Feminino , Humanos , Estudos Longitudinais , Masculino , Medicaid/estatística & dados numéricos , Medicare/estatística & dados numéricos , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Tempo , Estados Unidos , Adulto JovemRESUMO
OBJECTIVE: To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA). METHODS: This retrospective cohort study selected patients who had SEGA surgery and TSC claims between 2000-2011 from three large US nationwide claims databases. Selected patients were age 35 or less and had continuous health insurance in the year before and the year after their first SEGA surgery claim. The study examined the patients' demographic and clinical characteristics and estimated inpatient, outpatient, medication, and total medical costs paid by insurance companies for the pre-surgery year, post-surgery year, and other study periods, respectively. Repeated measures analysis and bootstrapping technique were used to assess the impact of the surgery on the direct medical costs. RESULTS: Select patients (n = 47) had a mean baseline age of 11.6 years and 66% were male. Many had seizures (91.0%), hydrocephalus (59.6%), vision disorders (38.3%), stroke and hemiparesis (36.2%), and shunt (34.0%) in the pre-surgery year. The mean direct medical costs were $8543 (inpatient: $3770; outpatient: $3473; medication: $1300) for the pre-surgery year, and $85,397 (inpatient: $71,562; outpatient: $11,497; medication: $2338) for the post-surgery year. With the exclusion of the costs during the surgery month, the inpatient, outpatient, medication, and total costs in the post-surgery year were 1.6-4.3 times as much as the costs in the pre-surgery year (inpatient: 4.3:1; outpatient: 2.5:1; medication: 1.6:1; total: 3.1:1, p < 0.05). Repeated measures analysis with bootstrapping confirmed a link between the surgery and increases in direct medical costs (p < 0.05). CONCLUSIONS: SEGA surgery had a substantial impact on direct medical costs. TSC patients with the surgery experienced significant post-surgery increases in their inpatient, outpatient, and medication costs. Additional research should be conducted to examine the surgery's cost-impact in a longer duration, or to compare the cost-effectiveness of the surgery vs other treatments.
Assuntos
Astrocitoma/economia , Astrocitoma/cirurgia , Gastos em Saúde/estatística & dados numéricos , Procedimentos Neurocirúrgicos/economia , Esclerose Tuberosa/economia , Adolescente , Adulto , Astrocitoma/etiologia , Neoplasias Encefálicas , Criança , Pré-Escolar , Feminino , Humanos , Revisão da Utilização de Seguros , Masculino , Estudos Retrospectivos , Esclerose Tuberosa/complicações , Adulto JovemRESUMO
OBJECTIVES: To assess and compare direct medical costs and medication compliance between patients with fibromyalgia who initiated duloxetine and patients with fibromyalgia who initiated pregabalin in 2008. METHODS: A retrospective cohort study design was used based on a large US national commercial claims database (2006 to 2009). Patients with fibromyalgia aged 18 to 64 who initiated duloxetine or pregabalin in 2008 and who had continuous health insurance 1 year preceding and 1 year following the initiation were selected into duloxetine cohort or pregabalin cohort based on their initiated agent. Medication compliance was measured by total supply days, medication possession ratio (MPR), and proportion of patients with MPR ≥ 0.8. Direct medical costs were measured by annual costs per patient and compared between the cohorts in the year following the initiation. Propensity score stratification and bootstrapping methods were used to adjust for distribution bias, as well as cross-cohort differences in demographic, clinical and economic characteristics, and medication history prior to the initiation. RESULTS: Both the duloxetine (n = 3,033) and pregabalin (n = 4,838) cohorts had a mean initiation age around 49 years, 89% were women. During the postindex year, compared to the pregabalin cohort, the duloxetine cohort had higher totally annual supply days (273.5 vs. 176.6, P < 0.05), higher MPR (0.7 vs. 0.5, P < 0.05), and more patients with MPR ≥ 0.8 (45.1% vs. 29.4%, P < 0.05). Further, relative to pregabalin cohort, duloxetine cohort had lower inpatient costs ($2,994.9 vs. $4,949.6, P < 0.05), lower outpatient costs ($8,259.6 vs. $10,312.2, P < 0.05), similar medication costs ($5,214.6 vs. $5,290.8, P > 0.05), and lower total medical costs ($16,469.1 vs. $20,552.6, P < 0.05) in the postinitiation year. CONCLUSIONS: In a real-world setting, patients with fibromyalgia who initiated duloxetine in 2008 had better medication compliance and consumed less inpatient, outpatient, and total medical costs than those who initiated pregabalin.
Assuntos
Fibromialgia/economia , Custos de Cuidados de Saúde , Adesão à Medicação , Tiofenos/economia , Ácido gama-Aminobutírico/análogos & derivados , Adolescente , Adulto , Estudos de Coortes , Bases de Dados Factuais/economia , Cloridrato de Duloxetina , Feminino , Fibromialgia/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Pregabalina , Estudos Retrospectivos , Tiofenos/uso terapêutico , Adulto Jovem , Ácido gama-Aminobutírico/economia , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
OBJECTIVES: To compare the prevalence rates of clinical conditions related to subependymal giant cell astrocytomas (SEGAs) before and after SEGA surgery among patients with tuberous sclerosis complex (TSC). METHODS: Based on three US national claims databases, we analyzed and compared the prevalence rates of 21 SEGA-related conditions (including seizures, hydrocephalus, headaches and stroke or hemiparesis) in the six months preceding surgery with the rates in the second through sixth post-surgery months and in the seventh through twelfth post-surgery months among TSC patients who underwent SEGA surgery during 2000-2009. Repeated measures analysis with a bootstrapping method was used to assess the surgery impact. RESULTS: Patients (N = 47) had a mean age of 11.5 years at their first SEGA surgery, and 66% were male. Compared with the six months preceding surgery, the post-surgery prevalence rates increased by 23-26% for seizures, 21-26% for hydrocephalus, 17-19% for headache and 6-9% for stroke or hemiparesis (all p < 0.05). Repeated measures analysis confirmed the impact of surgery on the prevalence rate of these five conditions (all p < 0.05). CONCLUSIONS: SEGA surgery has its important role in SEGA treatment. However, after SEGA surgery this group of TSC patients had increased prevalence rates of seizures, hydrocephalus, vision disorders, headaches, stroke or hemiparesis, and autism. Future research to examine the causes of these symptoms is imperative. LIMITATIONS: The study results have limitations in data source representativeness, coding accuracy, and study design.
Assuntos
Astrocitoma/cirurgia , Neoplasias Encefálicas/cirurgia , Bases de Dados Factuais , Esclerose Tuberosa/cirurgia , Astrocitoma/epidemiologia , Neoplasias Encefálicas/epidemiologia , Feminino , Humanos , Revisão da Utilização de Seguros , Masculino , Fatores de Tempo , Esclerose Tuberosa/epidemiologiaRESUMO
OBJECTIVE: To examine the outcomes following resection of subependymal giant cell astrocytoma (SEGA) among patients with SEGA-associated tuberous sclerosis complex (TSC). METHODS: Using three large US national healthcare claims databases, we retrospectively examined the outcomes of SEGA surgery among TSC patients who underwent SEGA surgery between 2000 and 2009. The examined outcomes were: prevalence rates of post-surgery SEGA, repeated SEGA surgery, and postoperative complications (surgical procedure complications, nervous system complications, postoperative infections, complications of subdural empyemas, and complications of epidural abscesses). Descriptive data analysis and two-sided one sample t-test for mean or proportion were used to assess the characteristics of patients and the outcomes of SEGA surgery. RESULTS: The selected patients (N = 47) had a mean age of 11.6 years at their first SEGA surgery and 66% were male. During the third through twelfth months following surgery, 34% had post-surgery SEGA (diagnosis) and 12% underwent repeated SEGA surgeries. During the first post-surgery year, 48.9% of patients developed postoperative complications (34.0% had complications relating to the surgical procedure, 12.8% had nervous system complications, 6.4% developed postoperative infections, 17.0% had complications of subdural empyemas, and 2.1% had complications of epidural abscesses). CONCLUSIONS: SEGA surgery was associated with statistically significant risks of developing post-surgery SEGA, requiring repeated SEGA surgery and developing postoperative complications. Future efforts in reducing these outcomes, either through improving surgical procedures or through alternative treatments, are urgently needed. LIMITATIONS: This study has its limitation in data source representativeness and measurement accuracy.
Assuntos
Astrocitoma/cirurgia , Neoplasias Encefálicas/cirurgia , Bases de Dados Factuais , Complicações Pós-Operatórias , Esclerose Tuberosa/cirurgia , Adolescente , Astrocitoma/epidemiologia , Neoplasias Encefálicas/epidemiologia , Criança , Feminino , Seguimentos , Humanos , Revisão da Utilização de Seguros , Masculino , Estudos Retrospectivos , Fatores de Tempo , Esclerose Tuberosa/epidemiologiaRESUMO
OBJECTIVES: This study examines the evolutionary impact of valsartan initiation on medical costs. METHODS: A retrospective time series study design was used with a large, US national commercial claims database for the period of 2004-2008. Hypertensive patients who initiated valsartan between the ages of 18 and 63, and had continuous enrollment for 24-month pre-initiation period and 24-month post-initiation period were selected. Patients' monthly medical costs were calculated based on individual claims. A novel time series model was devised with monthly medical costs as its dependent variables, autoregressive integrated moving average (ARIMA) as its stochastic components, and four indicative variables as its decomposed interventional components. The number of post-initiation months before a cost-offset point was also assessed. RESULTS: Patients (n = 18,269) had mean age of 53 at the initiation date, and 53% of them were female. The most common co-morbid conditions were dyslipidemia (52%), diabetes (24%), and hypertensive complications (17%). The time series model suggests that medical costs were increasing by approximately $10 per month (p < 0.01) before the initiation, and decreasing by approximately $6 per month (p < 0.01) after the initiation. After the 4th post-initiation month, medical costs for patients with the initiation were statistically significantly lower (p < 0.01) than forecasted medical costs for the same patients without the initiation. LIMITATIONS: The study has its limitations in data representativeness, ability to collect unrecorded clinical conditions, treatments, and costs, as well as its generalizability to patients with different characteristics. CONCLUSIONS: Commercially insured hypertensive patients experienced monthly medical cost increase before valsartan initiation. Based on our model, the evolutionary impact of the initiation on medical costs included a temporary cost surge, a gradual, consistent, and statistically significant cost decrease, and a cost-offset point around the 4th post-initiation month.
Assuntos
Anti-Hipertensivos/economia , Hipertensão/tratamento farmacológico , Tetrazóis/economia , Valina/análogos & derivados , Adolescente , Adulto , Anti-Hipertensivos/uso terapêutico , Custos e Análise de Custo , Bases de Dados Factuais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tetrazóis/uso terapêutico , Estados Unidos , Valina/economia , Valina/uso terapêutico , Valsartana , Adulto JovemRESUMO
OBJECTIVE: To examine medication dosing patterns of duloxetine and pregabalin among patients with fibromyalgia. METHODS: From a large US administrative claims database, commercially insured fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006 were selected. Initiation was defined as a 90-day medication gap, with the dispense date of the first initiation as the index date. All patients selected had continuous enrollment over the 12-month pre- and post-index periods, and were classified into the duloxetine or pregabalin cohorts based on their index agent. Initial daily dose, average daily dose over the 12-month post-index period, mean and median daily doses and daily costs of each of the first 12 prescriptions were examined for both the duloxetine and pregabalin cohorts. RESULTS: Both the duloxetine (n = 3773) and pregabalin (n = 4189) cohorts had a mean age of 50 years (median age: 52 vs. 53). The average initial daily dose was 55.7 mg for duloxetine and 161.5 mg for pregabalin. Over the 12-month post-index period, the average daily dose per patient was 55.6 mg for duloxetine and 195.7 mg for pregabalin. The average daily doses for the first 12 duloxetine prescriptions ranged 55.7-60.3 mg, with the mean daily costs between $3.77 and $4.59. For the first 12 pregabalin prescriptions, the average daily dose increased from 161.5 mg to 282.4 mg, while the average daily costs ranged between $4.30-4.61. CONCLUSIONS: Among patients with fibromyalgia, duloxetine and pregabalin initiators had different dosing patterns. The average daily dose for duloxetine was relatively stable over time, while pregabalin patients had significant dose increase over the 12-month post-index period.
Assuntos
Fibromialgia/tratamento farmacológico , Padrões de Prática Médica/estatística & dados numéricos , Tiofenos/administração & dosagem , Ácido gama-Aminobutírico/análogos & derivados , Adolescente , Inibidores da Captação Adrenérgica/administração & dosagem , Inibidores da Captação Adrenérgica/efeitos adversos , Inibidores da Captação Adrenérgica/economia , Adulto , Algoritmos , Analgésicos/administração & dosagem , Analgésicos/efeitos adversos , Analgésicos/economia , Comorbidade , Bases de Dados Factuais/estatística & dados numéricos , Relação Dose-Resposta a Droga , Custos de Medicamentos , Cloridrato de Duloxetina , Feminino , Fibromialgia/economia , Fibromialgia/epidemiologia , Humanos , Masculino , Adesão à Medicação , Pessoa de Meia-Idade , Pregabalina , Estudos Retrospectivos , Tiofenos/efeitos adversos , Tiofenos/economia , Adulto Jovem , Ácido gama-Aminobutírico/administração & dosagem , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/economiaRESUMO
OBJECTIVE: To examine the impact of medication choice between duloxetine or pregabalin on medication adherence and direct healthcare costs among patients with diabetic peripheral neuropathic pain (DPNP). METHODS: A retrospective cohort study design was used with a large US national administrative claims database. Commercially-insured DPNP patients aged 18-64 years who initiated duloxetine or pregabalin in 2006 were selected, with the first initiation date as the index date. All selected patients had 12 months continuous enrollment in the pre- and post-index periods, and were grouped into the duloxetine or pregabalin cohort based on the index agent. The duloxetine and pregabalin cohorts were constructed via propensity score stratification with similar demographics, co-morbid medical conditions, pre-index healthcare utilization and costs, and prior treatment patterns. Medication possession ratio (MPR), proportion of patients with MPR ≥ 0.8 and healthcare costs over the 12-month post-index period were compared between cohorts. RESULTS: Both the duloxetine (n = 794) and pregabalin (n = 1779) cohorts had a mean age of 56 years, and 58% of female. Common co-morbid conditions among duloxetine and pregabalin patients were cardiovascular disease (82.5 vs. 82.2%), neuropathic pain other than DPNP (71.1 vs. 72.7%), osteoarthritis (39.0 vs. 41.3%), and low back pain (29.4 vs. 30.5%). More than 73% of the patients had opioid use prior to the initiation of duloxetine or pregabalin. Among patients with similar demographic, clinical and economic characteristics, and prior treatment patterns, duloxetine-treated patients had significantly higher MPR (0.34 vs. 0.13), higher proportion of patients with MPR ≥ 0.8 (15.5 vs. 0.7%), and significantly lower total healthcare costs ($34,146 vs. 34,897) over the 12-month post-index period than pregabalin-treated patients (all p < 0.05). CONCLUSIONS: Commercially-insured DPNP patients initiating duloxetine had significantly higher medication adherence and lower healthcare costs than those initiating pregabalin.
Assuntos
Neuropatias Diabéticas/tratamento farmacológico , Neuropatias Diabéticas/economia , Custos de Cuidados de Saúde , Adesão à Medicação , Neuralgia/tratamento farmacológico , Neuralgia/economia , Tiofenos/uso terapêutico , Ácido gama-Aminobutírico/análogos & derivados , Adolescente , Adulto , Analgésicos/efeitos adversos , Analgésicos/economia , Analgésicos/uso terapêutico , Estudos de Coortes , Cloridrato de Duloxetina , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pregabalina , Estudos Retrospectivos , Tiofenos/efeitos adversos , Tiofenos/economia , Adulto Jovem , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/economia , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
OBJECTIVE: To examine and compare medication adherence and direct healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. METHODS: A retrospective analysis of commercially insured fibromyalgia patients aged 18 to 64 was conducted among those who initiated duloxetine or pregabalin between January 1, 2006 and December 31, 2006. The first initiation date was defined as the index date. All patients included had continuous enrollment in the 12-month pre- and post-index periods. Each individual was classified in the duloxetine or pregabalin cohort based on the initiating agent. The pregabalin cohort was constructed via propensity scoring controlling for differences in demographics, pre-index clinical and economic characteristics, and pre-index treatment patterns. Medication adherence (ie, medication possession ratio [MPR] and proportion of patients with MPR≥80%) and healthcare costs over the 12 months post-index period were examined between cohorts. RESULTS: The study cohorts included 3,711 duloxetine and 4,111 pregabalin patients with the mean age of 51 years. The common comorbidities included neuropathic pain other than diabetic peripheral neuropathic pain, low back pain, cardiovascular disease, headache, and osteoarthritis. Over 80% of the duloxetine or pregabalin initiators used opioids. Controlling for demographics, pre-index clinical and economic characteristics, and prior medication history, duloxetine patients had significantly higher MPR (0.7 vs. 0.5, P<0.05), higher proportion of patients with MPR≥80% (46.5% vs. 26.4%, P<0.05), but significantly lower total healthcare costs ($19,378 vs. $27,045, P<0.05) over the 12 months post-index period than pregabalin patients. CONCLUSION: Fibromyalgia patients on duloxetine had significantly higher medication adherence, but significantly lower direct healthcare costs than those on pregabalin.
Assuntos
Analgésicos/economia , Custos de Medicamentos , Fibromialgia , Adesão à Medicação/psicologia , Tiofenos/economia , Ácido gama-Aminobutírico/análogos & derivados , Adolescente , Adulto , Analgésicos/uso terapêutico , Estudos de Coortes , Cloridrato de Duloxetina , Feminino , Fibromialgia/tratamento farmacológico , Fibromialgia/economia , Fibromialgia/psicologia , Humanos , Masculino , Pessoa de Meia-Idade , Pregabalina , Estudos Retrospectivos , Tiofenos/uso terapêutico , Adulto Jovem , Ácido gama-Aminobutírico/economia , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
BACKGROUND: Rheumatoid arthritis (RA) causes pain and serious functional impacts and substantially affects patients' daily lives, including their ability to work. OBJECTIVE: This review examines recent studies of patients with RA treated with TNF antagonists and the impacts these therapies have on the workplace. METHODS: A total of 133 articles and 14 poster abstracts were reviewed that matched specific criteria. RESULTS/CONCLUSION: The results of early studies of TNF antagonists varied regarding their effects on patients with RA in the workplace. However, recent studies of adalimumab showed positive impacts across a range of workplace burdens. Treatments such as adalimumab may help employees with RA to remain in the workforce and lead to reduced workplace costs to the employers and employees.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Local de Trabalho/economia , Antirreumáticos/economia , Artrite Reumatoide/economia , Quimioterapia Combinada , Custos de Cuidados de Saúde , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/economia , Resultado do TratamentoRESUMO
PURPOSE: We examined the direct costs of erectile dysfunction (ED) empirically. MATERIALS AND METHODS: A naturalistic cohort study was done in 285,436 patients with ED and 51 health plans that covered 28 million lives nationwide from 1999 through 2001. Based on claims that had an ED related diagnosis code, procedure code or medication code we categorized the cost structure of ED care and calculated the annual costs of ED care per patient with ED, per user and per member monthly for individual and for all categories of ED care. RESULTS: A patient with ED in a health plan spent about an average of 83.91 dollars in 1999, 95.41 dollars in 2000 and 119.26 dollars in 2001 for ED care. In 2001, 37.08% of ED care costs per patient with ED were spent on phosphodiesterase type 5 (PDE-5) inhibitor therapy, 14.36% were spent on physician office visits, 10.19% were spent on diagnosis procedures, 8.45% were spent on testosterone hormone therapy, 3.85% were spent on penile prosthesis implantation, 4.41% were spent on intracavernous injection, 2.68% were spent on alprostadil pellet insertion and 0.81% was spent on vacuum erection devices. Of the 7 commonly used ED treatments PDE-5 inhibitor therapy has the lowest annual cost per user. CONCLUSIONS: In 2001 ED imposed a 122,669 dollars annual burden to a health plan with 100,000 members, that is or 0.108 dollars per member monthly. Each patient with ED spent 119.26 dollars annually for all ED related services or treatments. Of the 7 commonly used treatments PDE-5 inhibitor therapy had the lowest annual cost per user.
Assuntos
Disfunção Erétil/economia , Disfunção Erétil/terapia , Programas de Assistência Gerenciada/economia , Assistência ao Paciente/economia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Redução de Custos , Efeitos Psicossociais da Doença , Disfunção Erétil/diagnóstico , Custos de Cuidados de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Implante Peniano/economia , Inibidores de Fosfodiesterase/economia , Sistema de Registros , Estudos Retrospectivos , Estados UnidosRESUMO
OBJECTIVE: To compare medical and pharmacy costs and utilization between patients with diabetes who received insulin lispro versus regular human insulin. METHODS: A retrospective analysis of medical and pharmacy claims was conducted among continuously enrolled users of insulin lispro or regular insulin during the identification period, March 1, 2000, through February 28, 2001, within a large managed care organization. This study improved upon the methodology used in previous studies by (a) stratifying (rather than 1:1 matching) individuals by their likelihood to use insulin lispro using the propensity score binning technique, and (b) refining the study inclusion criteria to include only patients with 3 or more fills of the insulin under study (lispro or regular) to exclude individuals who may have been on either product for a short time. Because the propensity score binning technique groups patients with similar baseline characteristics within strata (bins) and not among individual patients, almost the entire available sample is retained in the analysis, unlike propensity score matching, where large numbers of patients can be excluded depending on the matching scheme. Therefore, the propensity score binning technique, because it uses more complete information, is less likely to produce biased results. Patients were grouped into 5 bins (quintiles) based on their estimated likelihood to receive insulin lispro rather than regular insulin. The propensity score model used baseline characteristics of age, gender, comorbidities, use of oral antidiabetic medications, prescription copayment, and diabetes-related costs and utilization. Overall cost and utilization differences (lispro minus regular insulin) during the 12-month follow-up period were calculated using weights inversely proportional to variances of within-bin differences. RESULTS: Of 6,436 patients, 1,972 (30.6%) received insulin lispro and 4,464 (69.4%) received regular insulin. The propensity score estimation produced 5 bins, each containing between 1,287 and 1,288 patients, utilizing all patients in the analysis. Patients in the lower-numbered propensity score quintiles were older, more likely to use oral antidiabetic medications, and had more comorbidities than those in the higher-numbered quintiles. As quintile number increased, the percentage of insulin lispro users also increased. The weighted mean annual cost difference (lispro minus regular insulin) per patient was + USD 79 (P < 0.001) for diabetes-related pharmacy cost, + USD 212 (P < 0.001) for total pharmacy cost, USD 75 (P < 0.857) for diabetes-related medical cost, USD 2,286 (P <0.011) for nondiabetes medical cost, and USD 2,327 (P = 0.072) for total medical cost. CONCLUSIONS: Compared with regular insulin users, insulin lispro users incurred higher diabetes-related and total pharmacy costs but lower nondiabetes medical costs and similar total medical costs. Fewer hospitalizations among insulin lispro as compared with regular insulin users contributed to lower nondiabetes medical costs and similar total medical costs.
Assuntos
Revisão de Uso de Medicamentos/estatística & dados numéricos , Insulina/análogos & derivados , Programas de Assistência Gerenciada/economia , Fatores Etários , Feminino , Seguimentos , Humanos , Insulina/economia , Insulina/uso terapêutico , Insulina Lispro , Revisão da Utilização de Seguros/estatística & dados numéricos , Seguro de Serviços Farmacêuticos/economia , Masculino , Estudos Retrospectivos , Fatores de TempoRESUMO
OBJECTIVES: The primary objectives of this research were to: (i) identify and present methodologies for estimating three types of 'cost-of-illness' measures using healthcare and disability claims data -- specifically 'cost of treatment', 'incremental cost of patient', and 'incremental cost of illness'; and (ii) perform a case-study analysis of these cost measures for women treated for stress urinary incontinence (SUI). STUDY DESIGN AND METHODS: In this paper, we discuss aspects of cost-of-illness methodologies in the context of SUI. We first distinguish between 'cost of treatment' (i.e. the costs of treating a specific condition), 'incremental cost of patient' (i.e. the additional costs associated with patients with a particular condition, irrespective of any comorbid conditions they may also have), and 'incremental cost of illness' (i.e. the additional costs resulting from a particular illness, as distinct from the costs of other conditions that the patient might have, including conditions which might have caused the illness in question). The latter case is in many ways the most complex to model, requiring controls for related causal conditions. We then applied these three methodologies by analysing the costs associated with SUI. Using data from a large employer claims database (n > 100 000), we estimated a series of regression models that reflected cost of treatment, incremental cost of patient, and incremental cost of illness for SUI. RESULTS: The three approaches yielded substantially different results. For many purposes the incremental cost-of-illness model provides the most appropriate results, as it controls for comorbid conditions, as well as patient demographics. On a per capita basis using the incremental cost-of-illness model, patients with SUI had direct costs that were 134% more than those for their controls and indirect costs that were 163% more than those for controls. Estimating costs for the average (i.e. mean) person results in dollar-termed estimates of the costs of SUI. In particular, we found that in 1998, the average direct medical cost of SUI was $US5642 and the indirect workplace cost of SUI was $US4208. CONCLUSIONS: Since the various methods yield substantially different results, it is important that the end user of cost-of-illness analyses of claims data have a clear purpose in mind when reporting the cost of the condition of concern. The incremental cost-of-illness measure for claims data has substantial advantages in terms of enhancing our understanding of the specific cost impact of SUI.